Side-by-side · Research reference
HCGvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED12/52 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
01Mechanism of Action
Parameter
HCG
Pancragen
Primary target
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Yes — preserves physiological glucose-insulin response
Origin
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
Rare with recombinant; possible with urinary-derived formulations
—
02Dosage Protocols
Parameter
HCG
Pancragen
Hypogonadotropic hypogonadism (monotherapy)
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
—
Combined therapy (hCG + FSH)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
—
Triple therapy (experimental)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
—
Cryptorchidism (pediatric)
500–4,000 IU IM 2–3×/week for 3–6 weeks
—
Evidence basis
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration to sperm appearance
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
—
Monitoring
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
HCG
Pancragen
Injection site reaction
Pain, erythema (mild, transient)
—
Gynecomastia
Aromatization of elevated testosterone to estradiol; dose-dependent
—
Testicular discomfort / Edema
Rapid testicular growth in hypogonadal males; usually self-limiting
—
Polycythemia
Elevated hematocrit from supraphysiological testosterone; monitor CBC
—
Mood / Libido changes
Variable; usually positive with normalization of testosterone
—
Acne / Oily skin
Androgen-mediated; dose-dependent
—
Prostate concerns
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
—
Antibody formation
Rare with recombinant; possible with urinary-derived
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Pancragen
—Relative Contraindications
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
HCG
Pancragen
1. Reconstitution (if lyophilized)
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Injection site
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Needle selection
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
—